Table 3

Investigator-driven criteria in the selection of phase II–III trial sites (phase III–IV for medical device)

CriteriaMeanUpper 95% CLLower 95% CLSD
Investigator recruitment/retention track record27.328.522.413.3
Investigator experience in previous trials22.723.821.612.0
Investigator interest22.4223.621.313.4
Investigator concurrent workload17.218.216.29.8
Investigator publication track record10.411.39.610.9
  • Respondents (N=341) were asked to divide 100 points across the above five criteria when selecting trial sites for phase III/IV (3/4) studies: Pharma, Biotech, CROs and CTUs answered for phase III (3) studies. Medical device and all others answered for phase IV (4) studies. There was evidence of a statistically significant difference in the level of importance of the five criteria (p<0.0001). The pattern of response (not shown here) appeared to be consistent across survey respondent groupings (ie, CTU vs CRO vs industry).

  • CL, confidence limit; CROs, clinical research organisations; CTUs, clinical trial units.